Vivos Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vivos Therapeutics, Inc. (NASDAQ: VVOS) on September 27, 2021, reporting events occurring on September 22, 2021. The filing addresses a definitive material agreement and the departure of a director.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and executive compensation arrangements rather than financial performance.
Material Changes
- Executive Sabbatical: Dr. G. Dave Singh, the Company's founder, Chief Medical Officer (CMO), and director, entered into a Sabbatical Agreement effective September 1, 2021, for a period of 12 months.
- Board Departure: Dr. Singh resigned from the Board of Directors effective September 22, 2021, to accept a role as an Adjunct Professor at Stanford University.
- Role Continuity: Dr. Singh retains his title as CMO and his compensation and benefits remain unchanged during the sabbatical. His duties are reduced to advising on clinical studies, collaborating on device development, and representing the Company at conferences.
- Future Reinstatement: The Board will determine 30 days prior to the sabbatical's expiration whether to reinstate Dr. Singh's full duties. Failure to reinstate constitutes an event of "Good Reason" under his employment agreement.
Outlook, Risks, and Management Commentary
Management believes Dr. Singh's appointment at Stanford University could result in new growth and exposure opportunities for the Company. The Company asserts that the sabbatical will not impact operations as Dr. Singh's primary duties have historically involved publishing, research, and lecturing. The filing includes standard forward-looking statement disclaimers regarding uncertainties and risks that could cause actual results to differ from expectations.
Key Facts for Investor Verification
- Dr. Singh's resignation from the Board is effective immediately, though he remains CMO.
- Compensation and benefits for Dr. Singh remain unchanged during the 12-month sabbatical.
- The Board has discretion to extend the sabbatical or modify duties upon expiration.
- The Nominating and Governance Committee may consider appointing a new director to fill the vacancy.
- Review the full Sabbatical Agreement (Exhibit 10.1) for specific milestone and performance objective details regarding incentive compensation.